Research Strategies, Trends, Opportunities in Pediatric Infectious Disease. Dr. Jaime C. Montoya, MD, MSc, PhD, CESO III Executive Director

Similar documents
East Asia Science and Innovation Area Joint Research Program (e-asia JRP) 1 st Scientific Advisory Council (SAC) Meeting

Sustainable Health Care Systems: Research and Innovation

Preventing Disease through Healthy Environments

Methodology. Annex 1.

Harmonized Region 1 Research and Development Agenda ( )

INSTITUT PASTEUR INSTITUT PASTEUR IS A PRIVATE, NON PROFIT, INSTITUTE DEDICATED TO RESEARCH & PUBLIC HEALTH

Infectious Diseases Institute Faculty Hires See below for research interests, areas of expertise and contact information

Duncan Holmes European Head Discovery Partnerships with Academia GlaxoSmithKline

EXECUTIVE SUMMARY EXECUTIVE SUMMARY. Global funding for neglected disease R&D increased for the first time since The survey.

Urban Planning, Environment and Health Initiative

CURRENT ISSUES IN INTELLECTUAL PROPERTY: A PATIENT PERSPECTIVE

World Congress on Infectious Diseases & Vaccines About the Conference: Aim Target Audience Conference Highlights

Opportunities for industry/smes in EU-funded health research

Clinical Trials in Taiwan Regulatory Achievement and Current Status

B20 Health Initiative

BIOLOGICAL BASIS OF PUBLIC HEALTH BMS505, Fall 2012 Syllabus

Malaria Research Capability Strengthening in Africa

Synagis (Palivizumab) Drug Prior Authorization Protocol

From IMI to IMI2 new models of collaborative research. Magda Chlebus, Science Policy, EFPIA Ljubljana, 23 May 2014

IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager

Government Bioscience Grant (GBG) Report October 2016 BROAD AGENCY ANNOUNCEMENTS CANCER

USAID DELIVER PROJECT Final Country Report. Indonesia

u n i versity of cope n h ag e n FP8 Position Paper

Post-Marketing Surveillance Studies

CIBIR: Center for Biomedical Research of La Rioja Eduardo Mirpuri, PhD. Biomedical Research Coordinator

Personalised Medicine Regulatory Issues

Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: economic-based decision-making Strutton D R, Stang P E

VECTOR CONTROL. Ms MA Groepe

Human Health and Nutrition

+ + + MALARIA HIV/AIDS TUBERCULOSIS LEISHMANIASIS CHAGAS DISEASE DENGUE EBOLA ZIKA

INTERNATIONAL COLLABORATION. S. Sinha Adviser Department of Biotechnology Ministry of Science & Technology Government of India

Workshop: Food Safety Challenges for Mediterranean Products. Climate change and food safety. Agustín Ariño

A global health guardian: climate change, air pollution and antimicrobial resistance

Genetic Testing Tool STH-PAS

IDSA is pleased to offer the following comments on specific priority areas identified by FDA:

BIO-INNOVATION FOR HEALTH: SOUTH AFRICA

Vector control. REGIONAL COMMITTEE Provisional Agenda item 8.4. SEA/RC70/10 Maldives 6 10 September July Seventieth Session

social, and population-based research conducted and supported by the National Institutes of Health (NIH). The

1.0 Abstract. Title. Synagis liquid 50 mg, 100 mg for Intramuscular Injection: Special Investigation in Immunocompromised Children with Synagis

Roche. New York City 7 December 2016

Knowing changes everything.

The Seventh Framework Programme ( )

Building Collaborative Research Success: Update to Senate on U of S Centres

Innovation in medical devices as response to Europe's healthcare challenges. Industry's viewpoint

A bold vision for 2025

Rare diseases in the 7th EU Framework Programme for Research and Technological Development

Innovative Medicines Initiative (IMI) Future funding opportunities. Catherine Brett, IMI Conferencia H2020 y Salud Madrid, Spain 8 November 2017

NATIONAL INSTITUTES OF HEALTH

Vaccine Clinical Trials

Vision and Strategic Research Agenda

DIAGNOSTIC R&D FOR NEGLECTED DISEASES

October 2018 CL 160/10 COUNCIL. Hundred and Sixtieth Session. Rome, 3-7 December Proposal for an International Year of Fruits and Vegetables

Antibody Discovery at Evotec

Role of DIAGNOSTICS in BIOPREPAREDNESS Mark Miller, MD Chief Medical Officer biomerieux

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

Globalization and Public Health. Dr Saman Waqar

Diagnostics: Learning from successful experiences which made it to market. Mark Miller, MD Chief Medical Officer biomérieux France

Microbial Biotechnology agustin krisna wardani

WHO Blood Regulators Network (BRN)

ANNUAL REPORT ( ) DESERT MEDICINE RESEARCH CENTRE

Changing the Practice of Medicine. The Novartis Institutes for BioMedical Research

Associate Dean for Research Florida Hospital Chair in cardiovascular Sciences

Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services

The New Diagnostics WG and The Global Plan to Stop TB

Climate Change: The Public Health Response

The Role of Research in Supporting Regulation of Biologicals: Building Bridges from Biomedical Discovery to Innovative Products

Components, sub-components and statistical topics of the FDES 2013

Introduction to Lassa fever

Alexandra Richardson, PhD, CLP April 2015

SUMMARY: in pictures PART 2 SECTION 2 MAJOR RISKS RESULTING FROM HUMAN ACTIVITIES. 20/22 countries report a lack of management for hazardous waste 31%

Globalized Drug Development: Big Diseases, Big Pharma, Big Solutions

Vulnerability assessment methodology : Part 1. Diarmid Campbell-Lendrum, Joy Guillemot & Bettina Menne

Investing in Discovery

For more information about the final programme, speakers or the EHFG conference please contact us directly!

Students should be able to explain how the spread of diseases can be reduced or prevented.

Global Health Technologies Invention saving lives

17th EHFG Electing Health The Europe We Want!

End poverty in all its forms everywhere

ONTARIO CLIMATE CHANGE AND HEALTH VULNERABILITY AND ADAPTATION ASSESSMENT GUIDELINES Workbook

ORACLE OTTAWA REGION FOR ADVANCED CARDIOVASCULAR RESEARCH EXCELLENCE STRATEGIC DIRECTIONS

FP7 Cooperation Work Programme: Health-2011 Topics and contact points

Planning and Adaptation in the Health Sector: Contribution by WHO

Disruptive Innovation at the NIH. Kathy Hudson, Ph.D. Deputy Director Science, Outreach, and Policy National Institutes of Health

Published on Horizon 2020 ( Tuesday, 13 January, Ebola virus. Latest on Silver (September, 2015)

Newborn Screening Policy Development in the United States

The Innovative Medicines Initiative Europe s partnership for health. Tek-Ang LIM, 20 June 2018, Brussels

International Collaborations in Pediatrics: FDA and EMA growing together March 2018

15.3 Applications of Genetic Engineering

What are the origins of medical practice? Humans have been involved with medical biotechnology

Public private partnerships

Tuesday 7 June 2016 Afternoon

TERMS OF REFERENCE. The form and function of the Stop TB Partnership Working Group on New Drugs, Its Core Group (CG), Subgroups and Secretariat

ENDOSCOPE REPROCESSING AND INFECTION CONTROL FOR ENDOSCOPY

Dialogue 1: Partnerships in support of strengthening health systems: Building resilience to pandemics 1

The Impact of Translational Research

What Can I Do With My Data?

NIH Institutes and Areas of SBIR Research: (shown in order of FY 2010 Funding amounts)

Funding neglected disease R&D The next hurdle

MPE8 antibody hits the Achilles heel of the viruses Davide Corti

Nee-Kofi Mould-Millman, MD. Assistant Professor, Dept of Emergency Medicine Senior Investigator, Center for Global Health

Transcription:

Research Strategies, Trends, Opportunities in Pediatric Infectious Disease Dr. Jaime C. Montoya, MD, MSc, PhD, CESO III Executive Director

Current state of S and T in the country Current state of research in general and for pediatric infectious diseases in the country Today s presentation

Research Priorities based on the NUHRA Research opportunities in pediatric infectious diseases, its importance and relevance Today s presentation

380 researchers, scientists and engineers (RSE) per million 1% GDP Expenditure on R&D (GERD) 180 RSEs (2009) 270 RSEs (2013) Photo credit: https://www.vecteezy.com/vector-art/88744-outlinescience-icons-vector Science for Change Program (S4CP) DEPARTMENT OF SCIENCE AND TECHNOLOGY

Malasakit Pagbabago Kaunlaran AmBisyon Natin 2040 Harmonized National R&D Agenda National Integrated Basic Research Agenda (NIBRA) Health Agriculture, Aquatic and Natural Resources (AANR) Industry Energy and Emerging Technology Disaster Risk Reduction and Climate Change Adaptation (DRR CCA)

Science For The People R&D to Address Pressing Problems R&D for Productivity Accelerated R&D Program for Capacity Building of Research and Development Institutions and Industrial Competitiveness Assistance to the Production Sector R&D to Tap, Manage and Store Renewable Energy Resources R&D to Apply New Technologies Across Sectors Disaster Risk Reduction and Climate Change Maximize Utilization of R&D Results Through Technology Transfer and/or Commercialization Upgrading of Facilities and Improvement of S&T Services Human Resource Development for Science & Technology Capacitate and Utilize Institutions in the Regions SUCs who do R&D and Develop Human Resources in S&T Collaboration with industry, academe and international institutions

Republic Act 10532: PNHRS Act of 2013 On May 7, 2013, His Excellency President Benigno Noynoy S. Aquino signed Republic Act 10532 or An Act Institutionalizing the Philippine National Health Research System of 2013. The Philippine National Health Research System (PNHRS) is the national integrated framework for health research in the country The PCHRD is recognized and mandated as the national coordinating body for health research in the country

8

Harmonized National R&D Agenda 2017-2022 -----Health----- RESEARCH PRIORITIES for HEALTH S&T Diagnostics Drug discovery and development Functional foods Hospital equipment and biomedical devices Information and communication technology for health Dengue Nutrition and food quality and safety Disaster risk reduction Climate Change Adaptation Genomics/Molecular technology (Platform technology across research priorities)

Infectious diseases account for 15 million deaths per year worldwide, and disproportionately affect young people, elderly people, and the poorest sections of society. -The Lancet

Goal 3: Ensure healthy lives and promote well-being for all at all ages Sustainable Development Goals

1. Pneumonia 6. Accidental drowning and submersion 2. Diarrhea and gastroenteritis of presumed infectious origin 7. Dengue Fever and Dengue- hemorrhagic fever 3. Congenital anomalies 8. Chronic lower respiratory diseases 4. Septicemia 9. Meningitis 5. Other diseases of the nervous system 10. Leukemia Top 10 Mortality Causes in Children 1-4 years old

1. Pneumonia 6. Congenital anomalies 2. Dengue Fever and Denguehemorrhagic fever 3. Accidental drowning and submersion 4. Other diseases of the nervous system 7. Leukemia 8. Meningitis 9. Septicemia 5. Transport accidents 10. Diarrhea and gastroenteritis of presumed origin Top 10 Mortality Causes in Children 5-9 years old

1. Pneumonia 6. Dengue Fever and Dengue-hemorrhagic fever 2. Accidental drowning and submersion 3. Other diseases of nervous system 7. Chronic rheumatic heart disease 8. Leukemia 4. Transport accidents 9. Septicemia 5. Congetial anomalies 10. Nephritis nephrotic syndrome and neph Top 10 Mortality Causes in Children 10-14 years old

Pneumonia, diarrhea and congenital anomalies are the leading causes of death among children below 5 years of age Bacterial sepsis, pneumonia, and respiratory distress are the top leading causes of infant mortality. Philippine Health Statistics 2012

National Unified Health Research Agenda NUHRA, 2011-2016 NUHRA, 2006-2010 National Health R&D Agenda, 2000-2005

Harmonized National R&D Agenda 2017-2022 -----Health----- NUHRA - National roadmap for health research in the country - Provides focus and direction for health research and development efforts - Serve as guide for policy makers, funding and donor agencies and researchers - Provides evidence-based solutions to pressing health problems - Serve as basis to maximize resource utilization and minimize duplication of research efforts Health S & T research agenda will be integrated in the NUHRA

Research Priorities Four major areas: 1. Health Technology Development 2. Health Financing 3. Health Service Delivery 4. Socio-environmental health concerns NUHRA

Harmonized National R&D Agenda 2017-2022 -----Health----- Research Priorities for Health Tech Devt a consolidation of health research priorities of the DOST agencies each agency conducted research priority setting activities - guided the DOST s S and T thrusts, emerging and re-emerging health concerns and other national and global development concerns - consultations done with experts and stakeholders from the public and private sectors through meetings, workshops, FGDs

Diagnostics Health Technology Development Development of diagnostic kits for priority infectious diseases and non-communicable diseases for the early detection and/or prediction of disease and mortality, utilizing existing technologies that are off-patent or lapsed technology and/or novel technology. Such technology will also look at genetic or biological markers associated with DM, CVD, and cancer National Unified Health Research Agenda

Diagnostics Health Technology Development Priority diseases: Infectious diseases 1.Dengue and dengue-like illness 2.Multidrug Resistant/Extensively Drug Resistant Tuberculosis (MDR/ XDR TB) 3.Drug-Resistant Malaria 4. Influenza-like illness 5. Leptospirosis 6. Sepsis 7. Human immunodeficiency virus (HIV) 8. Hepatitis National Unified Health Research Agenda

Drug Discovery and Development Health Technology Development Researches will aim to discover new drugs which can be developed up to the pre-clinical stage. It will involve the discovery of compounds or molecular drug targets (genomics) that can serve as candidates for drug development. Drugs will be developed for common infectious diseases and lifestyle related disorders. National Unified Health Research Agenda

Harmonized National R&D Agenda 2017 -----Health----- Drug Discovery and Development Development of standardized herbal drugs and discovery of new drugs from local sources for development up to the pre-clinical stage. Drugs will be developed for: Infectious diseases o Bacterial infections (M. tuberculosis, Enterococcus faecium, S. aureus, Klebsiella pneumoniae, Acinetobacter baumanii)

Harmonized National R&D Agenda 2017 -----Health----- Drug Discovery and Development o Viral diseases (e.g. dengue influenza) o Fungal infections Non-communicable diseases o Lifestyle-elated diseases (e.g. diabetes, CVDs, etc.) o Cancer (colon, breast, lung) o Respiratory diseases o Neurodegenerative diseases

Harmonized National R&D Agenda 2017-2022 -----Health----- Nutrition and food quality and safety Food quality and safety refers to the assurance that food will not cause harm to the consumer when prepared or eaten according to its intended use. Major nutrition problems in the country o Micronutrient deficiencies o Macronutrient deficiencies o Overnutrition o Nutrition related diseases

Harmonized National R&D Agenda 2017-2022 -----Health----- Nutrition and food safety Specific topics 2018 Food fortification o o Fortified multi-nutrient growth mix products Rice extrudate Development/revision of nutrition tools and standards o o o Nutritional guidelines Food exchange list Body composition assessment

Harmonized National R&D Agenda 2017-2022 -----Health----- Nutrition and food safety 2018 Specific topics Nutritional assessment and monitoring o o In-depth and correlation studies (dietary risk factors to non-communicable diseases) Nutrition surveys Designing nutrition intervention programs o Nutrition delivery system for complementary feeding promotion

Harmonized National R&D Agenda 2017-2022 -----Health----- Nutrition and food safety 2018 Specific topics Food quality and safety o enhancement of food composition database for dietary exposure assessment o exposure assessment of selected nutrients, food contaminants, and food additives in commonly consumed foods

Harmonized National R&D Agenda 2017-2022 -----Health----- Dengue Reduction of transmission through vector control Involves targeting the mosquito vector/s in the habitats of its larval and adult stages and where human vector contact may occur Develop an early warning system by developing alert levels integrating entomological, environmental and socio-demographic data for the prediction of dengue outbreak.

Harmonized National R&D Agenda 2017-2022 -----Health----- Dengue Vector biology Vector surveillance and integrated vector management (IVM) Dengue case management Dengue outbreak management

Genomics / Molecular Technology Health Technology Development Molecular and genomics technologies use the information in the human genome in the design of vaccines, therapeutics, and diagnostic devices or products. National Unified Health Research Agenda

Genomics / Molecular Technology Priority diseases 1. Cardiovascular Diseases (CVD) 2. Infectious Diseases (TB, Dengue, and Influenza) 3. Cancer 4. Diabetes 5. Neurodegenerative Diseases National Unified Health Research Agenda

Science for Change Program (S4CP) DEPARTMENT OF SCIENCE AND TECHNOLOGY Photo credit:http://www.ecovallee-cotedazur.com/key-stakes/economy-and-employment/enabling-innovation; http://www.cosmetic-360.com/en/pages/open-innovation--68.html

S4CP endeavors to significantly accelerate Science, Technology and Innovation (STI) in the country through massive increase in investment on S&T Human Resource Development and R&D through the program A. Program Expansion in 10 areas B. New Programs in 5 areas C. S&T Human Resource Development D. Accelerated R&D Program for Capacity Building of Research and Development Institutions and Industrial Competitiveness.

www.projects.pchrd.dost.gov.ph Submit your proposal

/dostpchrd @DOST_PCHRD www.pchrd.dost.gov.ph Connect with us!